Remdesivir treatment increased the likelihood of clinical improvement in COVID-19 patients on low-flow oxygen or no oxygen, according to a new study by the Johns Hopkins University School of Medicine, the Johns Hopkins Bloomberg School of Public Health, HCA Healthcare, and Genospace.

These results support the use of remdesivir for hospitalized COVID-19 patients on no or low-flow oxygen.

Routine initiation of remdesivir in more severely ill patients is unlikely to be beneficial.

Of 96,859 COVID-19 patients, 42,473 (43.9%) received at least one remdesivir dose.

The median age of remdesivir recipients was 65 years, 23,701 (55.8%) were male and 22,819 (53.7%) were non-white.

Matches were found for 18,328 patients (43.2%).

Remdesivir recipients were significantly more likely to achieve clinical improvement by 28 days.

Read More